pirfenidone has been researched along with Weight Loss in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Cordova, FC; Criner, GJ; Dorey-Stein, ZL; Galli, JA; Shapiro, W; Zhao, H | 1 |
| Cho, YJ; Kim, HJ; Kim, TH; Kim, YW; Kwon, BS; Lee, CT; Lee, JH; Lee, YJ; Lim, SY; Park, JS; Shin, YY; Song, MJ | 1 |
| Culver, DA; Glennie, J; Li, M; Olman, MA; Perelas, A; Scheraga, RG; van Kerkhove, K | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Katano, T; Kitamura, H; Oda, T; Ogura, T; Okuda, R; Sadoyama, S; Sekine, A; Shintani, R; Tabata, E; Takemura, T; Yamakawa, H | 1 |
| Ehlers-Tenenbaum, S; Herth, FJ; Heussel, CP; Kahn, N; Kreuter, M; Oltmanns, U; Palmowski, K; Puderbach, M; Schnabel, PA; Träger, A; Warth, A; Wenz, H; Wiebel, M | 1 |
| Fukuda, Y; Goto, H; Hanibuchi, M; Morizumi, S; Nishioka, Y; Sato, S; Takahashi, M; Toyoda, Y | 1 |
| Robinson, HC | 1 |
7 other study(ies) available for pirfenidone and Weight Loss
| Article | Year |
|---|---|
Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
Topics: Aged; Antifibrotic Agents; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Transplantation; Male; Perioperative Period; Pyridones; Retrospective Studies; Vital Capacity; Waiting Lists; Weight Loss | 2021 |
Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Carbon Monoxide; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity; Weight Loss | 2022 |
Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyridones; Severity of Illness Index; Weight Loss | 2019 |
Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Anorexia; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Logistic Models; Lung; Male; Middle Aged; Multivariate Analysis; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity; Weight Loss | 2019 |
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Expectorants; Fatigue; Female; Gastrointestinal Diseases; Germany; Humans; Idiopathic Pulmonary Fibrosis; Male; Medication Adherence; Middle Aged; Pyridones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Vital Capacity; Weight Loss | 2014 |
A Patient with Idiopathic Pleuroparenchymal Fibroelastosis Showing a Sustained Pulmonary Function due to Treatment with Pirfenidone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pleural Diseases; Pyridones; Radiography, Thoracic; Respiratory Physiological Phenomena; Time Factors; Treatment Outcome; Vital Capacity; Weight Loss | 2016 |
Respiratory Conditions Update: Restrictive Lung Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Continuous Positive Airway Pressure; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Obesity Hypoventilation Syndrome; Oxygen Inhalation Therapy; Polysomnography; Pyridones; Respiratory Function Tests; Respiratory Therapy; Sleep Apnea, Obstructive; Weight Loss | 2016 |